| 000 | 02447 a2200625 4500 | ||
|---|---|---|---|
| 005 | 20250518003655.0 | ||
| 264 | 0 | _c20190610 | |
| 008 | 201906s 0 0 eng d | ||
| 022 | _a1474-5488 | ||
| 024 | 7 |
_a10.1016/S1470-2045(18)30685-5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRobak, Tadeusz | |
| 245 | 0 | 0 |
_aFrontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. _h[electronic resource] |
| 260 |
_bThe Lancet. Oncology _c11 2018 |
||
| 300 |
_a1449-1458 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 | _aAsia |
| 650 | 0 | 4 |
_aBortezomib _xadministration & dosage |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 | _aEurope |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Mantle-Cell _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aNorth America |
| 650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
| 650 | 0 | 4 | _aProgression-Free Survival |
| 650 | 0 | 4 |
_aRituximab _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aVincristine _xadministration & dosage |
| 700 | 1 | _aJin, Jie | |
| 700 | 1 | _aPylypenko, Halyna | |
| 700 | 1 | _aVerhoef, Gregor | |
| 700 | 1 | _aSiritanaratkul, Noppadol | |
| 700 | 1 | _aDrach, Johannes | |
| 700 | 1 | _aRaderer, Markus | |
| 700 | 1 | _aMayer, Jiri | |
| 700 | 1 | _aPereira, Juliana | |
| 700 | 1 | _aTumyan, Gayane | |
| 700 | 1 | _aOkamoto, Rumiko | |
| 700 | 1 | _aNakahara, Susumu | |
| 700 | 1 | _aHu, Peter | |
| 700 | 1 | _aAppiani, Carlos | |
| 700 | 1 | _aNemat, Sepideh | |
| 700 | 1 | _aCavalli, Franco | |
| 773 | 0 |
_tThe Lancet. Oncology _gvol. 19 _gno. 11 _gp. 1449-1458 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S1470-2045(18)30685-5 _zAvailable from publisher's website |
| 999 |
_c28966045 _d28966045 |
||